REVEAL WHAT OTHER ASSAYS MISS
GSL is proud to offer next-generation high-sensitivity protein biomarker analysis through our partnership with Alamar Biosciences and adoption of the NULISA™ platform.
The NULISA™ platform combines the advanced ARGO™ HT automation system with a next-generation immunoassay technology to deliver ultra-sensitive protein detection at attomolar levels.
Built on Alamar Biosciences’ proprietary dual-capture-and-release chemistry, NULISA achieves ultra-low detection limits and broad multiplexing for critical biomarkers in plasma, CSF and other biofluids, as well as some critical tissues such as brain homogenates.
KEY FEATURES
ATTOMOLAR-LEVEL SENSITIVITY
Detect low- to sub-fg/mL proteins
BROAD DYNAMIC RANGE
Up to ~12 logs
DUAL-CAPTURE TECHNOLOGY
~10,000× background suppression
FULLY AUTOMATED WORKFLOW
Reduce hands-on time and improve consistency
ARGO™ HT AT A GLANCE
Ultra-Sensitive Low-Level Protein Detection
A fully automated immunoassay platform leveraging oligonucleotide- linked antibodies and dual magnetic capture technology to suppress background signal and achieve up to 10,000-fold greater sensitivity than conventional proximity assays.
Designed for both single-plex and high-plex protein analysis, enabling the quantification of dozens to hundreds of proteins within a single run.
Compatible with immuno-sequencing (NGS) readouts for high-plex applications, supporting panels of 200+ protein targets.
PANELS ON OFFER
NULISAseq™ MOUSE PANEL 120
Comprehensive inflammation profiling in preclinical models using the largest multiplexed protein panel for mouse studies. Enables deep insights from small- volume samples.
NULISAseq™ CNS DISEASE PANEL 120
Simultaneously measure 120 CNS-related proteins from just 25 µL of sample with fg/mL sensitivity -ideal for early detection and phenotypic differentiation in neurological research.
NULISAseq™ INFLAMMATION PANEL 250
Extensive coverage of inflammatory pathways with unmatched sensitivity and dynamic range. Designed to distinguish healthy from disease states across complex cytokine networks.
NULISAseq™ INFLAMMATION PANEL AQ
Quantify over 150 inflammatory biomarkers with absolute values and fg/mL sensitivity. Ideal for longitudinal and multi-site clinical studies, including dose- response evaluations.
NULISAqpcr™ SINGLE-PLEX ASSAYS
Ultra-sensitive, attomolar level detection of key biomarkers like IL-4 and NfL for precise monitoring of immune and neurological conditions.
SAMPLE TO INSIGHT WORKFLOW
Sample Input
Low volume requirement (~10 µL)
Automated Processing
ARGO™ HT platform
Data Generation
qPCR or NGS readout
Integrated Analytics
Actionable biological insights
- Minimal manual intervention
- High reproducibility
- Scalable for large cohort studies
PROVEN PERFORMANCE
The NULISA™ platform has been validated in peer-reviewed research, including a Nature Communications publication demonstrating its sensitivity and performance.
WHY CHOOSE NULISA™ AT GSL?
Industry-leading attomolar sensitivity
Automated, scalable workflows for high- throughput studies
Flexible qPCR and NGS assay formats
Expertise in biomarker discovery and translation
